Treatment outcomes and response pattern of ustekinumab in Korean patients with psoriasis: A retrospective single-center study

Jongwook Oh, Tae Gyun Kim, Min Geol Lee

Research output: Contribution to journalArticle

Abstract

Background: Psoriasis is a chronic immune-mediated inflammatory skin disease affecting 2-3% of the worldwide population. Ustekinumab, an IL-12/23p40 inhibitor, is a biologic reported to be effective and safe in treating psoriasis. However, there are limited data on the treatment outcomes of ustekinumab in patients with psoriasis in Korea. Objectives: To evaluate the treatment outcomes and response pattern of ustekinumab in patients with psoriasis in Korea. Methods: This was a retrospective single-center study. Eighty-four patients with psoriasis treated with ustekinumab were analyzed. Each patient's medical records, psoriasis area and severity index (PASI) score, and body surface area were reviewed at baseline and up to week 52. Results: A total of 84 patients were included (male:female= 1.8:1). The mean age was 44.5 years. At week 16, 86.7% achieved PASI75, 59.0% achieved PASI90, and 20.5% achieved PASI100. By week 16, 84.8% of subjects had attained PASI75 for the head region, whereas 79.0% had attained it for the lower extremities, indicating a relatively slower treatment response of psoriatic lesions on the lower extremities. Four patients discontinued treatment due to lack of effect. No severe adverse events occurred during the follow-up period. Conclusion: Ustekinumab demonstrated highly effective and safe treatment profiles in Korean psoriatic patients, consistent with the previous reports from mainly Western countries. Psoriasis severity and treatment responsiveness may vary with body region. (Korean J Dermatol 2019;57(8):441~447).

Original languageEnglish
Pages (from-to)441-447
Number of pages7
JournalKorean Journal of Dermatology
Volume57
Issue number8
Publication statusPublished - 2019 Sep

Fingerprint

Psoriasis
Korea
Lower Extremity
Body Regions
Body Surface Area
Therapeutics
Interleukin-12
Ustekinumab
Skin Diseases
Medical Records
Head
Population

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

@article{6a3ea35e00614ae48d27a1681caaa75c,
title = "Treatment outcomes and response pattern of ustekinumab in Korean patients with psoriasis: A retrospective single-center study",
abstract = "Background: Psoriasis is a chronic immune-mediated inflammatory skin disease affecting 2-3{\%} of the worldwide population. Ustekinumab, an IL-12/23p40 inhibitor, is a biologic reported to be effective and safe in treating psoriasis. However, there are limited data on the treatment outcomes of ustekinumab in patients with psoriasis in Korea. Objectives: To evaluate the treatment outcomes and response pattern of ustekinumab in patients with psoriasis in Korea. Methods: This was a retrospective single-center study. Eighty-four patients with psoriasis treated with ustekinumab were analyzed. Each patient's medical records, psoriasis area and severity index (PASI) score, and body surface area were reviewed at baseline and up to week 52. Results: A total of 84 patients were included (male:female= 1.8:1). The mean age was 44.5 years. At week 16, 86.7{\%} achieved PASI75, 59.0{\%} achieved PASI90, and 20.5{\%} achieved PASI100. By week 16, 84.8{\%} of subjects had attained PASI75 for the head region, whereas 79.0{\%} had attained it for the lower extremities, indicating a relatively slower treatment response of psoriatic lesions on the lower extremities. Four patients discontinued treatment due to lack of effect. No severe adverse events occurred during the follow-up period. Conclusion: Ustekinumab demonstrated highly effective and safe treatment profiles in Korean psoriatic patients, consistent with the previous reports from mainly Western countries. Psoriasis severity and treatment responsiveness may vary with body region. (Korean J Dermatol 2019;57(8):441~447).",
author = "Jongwook Oh and Kim, {Tae Gyun} and Lee, {Min Geol}",
year = "2019",
month = "9",
language = "English",
volume = "57",
pages = "441--447",
journal = "Korean Journal of Dermatology",
issn = "0494-4739",
publisher = "Korean Dermatological Association",
number = "8",

}

Treatment outcomes and response pattern of ustekinumab in Korean patients with psoriasis : A retrospective single-center study. / Oh, Jongwook; Kim, Tae Gyun; Lee, Min Geol.

In: Korean Journal of Dermatology, Vol. 57, No. 8, 09.2019, p. 441-447.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment outcomes and response pattern of ustekinumab in Korean patients with psoriasis

T2 - A retrospective single-center study

AU - Oh, Jongwook

AU - Kim, Tae Gyun

AU - Lee, Min Geol

PY - 2019/9

Y1 - 2019/9

N2 - Background: Psoriasis is a chronic immune-mediated inflammatory skin disease affecting 2-3% of the worldwide population. Ustekinumab, an IL-12/23p40 inhibitor, is a biologic reported to be effective and safe in treating psoriasis. However, there are limited data on the treatment outcomes of ustekinumab in patients with psoriasis in Korea. Objectives: To evaluate the treatment outcomes and response pattern of ustekinumab in patients with psoriasis in Korea. Methods: This was a retrospective single-center study. Eighty-four patients with psoriasis treated with ustekinumab were analyzed. Each patient's medical records, psoriasis area and severity index (PASI) score, and body surface area were reviewed at baseline and up to week 52. Results: A total of 84 patients were included (male:female= 1.8:1). The mean age was 44.5 years. At week 16, 86.7% achieved PASI75, 59.0% achieved PASI90, and 20.5% achieved PASI100. By week 16, 84.8% of subjects had attained PASI75 for the head region, whereas 79.0% had attained it for the lower extremities, indicating a relatively slower treatment response of psoriatic lesions on the lower extremities. Four patients discontinued treatment due to lack of effect. No severe adverse events occurred during the follow-up period. Conclusion: Ustekinumab demonstrated highly effective and safe treatment profiles in Korean psoriatic patients, consistent with the previous reports from mainly Western countries. Psoriasis severity and treatment responsiveness may vary with body region. (Korean J Dermatol 2019;57(8):441~447).

AB - Background: Psoriasis is a chronic immune-mediated inflammatory skin disease affecting 2-3% of the worldwide population. Ustekinumab, an IL-12/23p40 inhibitor, is a biologic reported to be effective and safe in treating psoriasis. However, there are limited data on the treatment outcomes of ustekinumab in patients with psoriasis in Korea. Objectives: To evaluate the treatment outcomes and response pattern of ustekinumab in patients with psoriasis in Korea. Methods: This was a retrospective single-center study. Eighty-four patients with psoriasis treated with ustekinumab were analyzed. Each patient's medical records, psoriasis area and severity index (PASI) score, and body surface area were reviewed at baseline and up to week 52. Results: A total of 84 patients were included (male:female= 1.8:1). The mean age was 44.5 years. At week 16, 86.7% achieved PASI75, 59.0% achieved PASI90, and 20.5% achieved PASI100. By week 16, 84.8% of subjects had attained PASI75 for the head region, whereas 79.0% had attained it for the lower extremities, indicating a relatively slower treatment response of psoriatic lesions on the lower extremities. Four patients discontinued treatment due to lack of effect. No severe adverse events occurred during the follow-up period. Conclusion: Ustekinumab demonstrated highly effective and safe treatment profiles in Korean psoriatic patients, consistent with the previous reports from mainly Western countries. Psoriasis severity and treatment responsiveness may vary with body region. (Korean J Dermatol 2019;57(8):441~447).

UR - http://www.scopus.com/inward/record.url?scp=85075145252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075145252&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85075145252

VL - 57

SP - 441

EP - 447

JO - Korean Journal of Dermatology

JF - Korean Journal of Dermatology

SN - 0494-4739

IS - 8

ER -